Beta Bionics (NASDAQ:BBNX) executives used a conference presentation to outline the company’s strategy in insulin delivery, emphasizing automation, pharmacy reimbursement, and an expanding commercial ...

Add Yahoo as a preferred source to see more of our stories on Google. Beta Bionics said it plans to integrate its ILet Bionic Pancreas automated insulin delivery system with a glucose-ketone sensor ...

Beta Bionics plans to integrate its iLet Bionic Pancreas with Abbott's upcoming dual glucose-ketone sensor for enhanced diabetes management. Beta Bionics, Inc. has announced plans to integrate its ...

Beta Bionics, Inc. BBNX recently entered into a strategic agreement with Abbott Laboratories ABT to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's upcoming ...

Orange County is about to see the first initial public offering of 2025. Irvine-based medical device company Beta Bionics Inc. on Jan. 6 filed an S-1 with the Securities and Exchange Commission to ...

Patch pump under development with commercialization expected by the end of 2027 One of Orange County’s fastest-growing public companies only went public two months ago. Beta Bionics Inc.’s concept of ...

Beta Bionics, Inc. (BBNX) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement. BBNX is commercializing an approved insulin delivery device for ...

Description: This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a ...

Two manufacturers of automated insulin delivery (AID) systems, Tandem Diabetes Care and Beta Bionics, have updated their products to integrate with the Dexcom G7 continuous glucose monitoring (CGM) ...